Clinical Research & Trials Nursing
in the GCC

All nurses working in UAE — including those in clinical research roles — must hold a valid UAE nursing licence from either the Dubai Health Authority (DHA) or the Department of Health Abu Dhabi (DOH), depending on the emirate. Clinical research coordinator roles at hospitals in Dubai require DHA registration; roles in Abu Dhabi (including Cleveland Clinic Abu Dhabi) require DOH.

• Complete DataFlow primary source verification of your credentials
• Pass the relevant Prometric licensing examination (DHA or MOH/DOH)
• Submit GCP certificate alongside your licence application — many research hospitals require this on file
• Research-specific scope clarifications may be needed from DHA/DOH for procedures like study drug administration or Phase I interventional procedures
• ACRP/SOCRA certifications are not required for licensure but are strongly preferred by employers

Saudi Arabia requires all nurses to register with the Saudi Commission for Health Specialties (SCFHS). For research nursing, KFSH&RC and KAIMRC have their own internal credentialing processes in addition to SCFHS registration. The Saudi Food and Drug Authority (SFDA) oversees clinical trial regulations in the Kingdom.

• SCFHS registration is mandatory — complete DataFlow and pass the Saudi licensing exam
• KFSH and KAIMRC require additional institutional research credentialing before conducting study procedures
• GCP training certificate required — many sites prefer KFSH-provided or NIHR GCP training
• SFDA Good Clinical Practice guidelines align with ICH-GCP and are enforced for all registered trials
• Arabic language proficiency is advantageous for conducting informed consent with Saudi participants

Qatar requires nursing licensure through the Qatar Council for Healthcare Practitioners (QCHP). Both HMC and Sidra Medicine have dedicated research offices that require additional research credentialing beyond the standard QCHP licence.

• QCHP registration via DataFlow — primary source verification of all qualifications
• GCP certification is explicitly required by HMC Research Office for all research staff
• HMC Research Ethics Committee (REC) provides site-level oversight; all staff conducting research must be listed on the approved REC application
• Sidra Medicine aligns with Weill Cornell Medicine research standards — high quality research environment with competitive packages
• Qatar University IRB oversees university-affiliated research; joint HMC-QU studies are common

Clinical research nursing is less developed in Oman, Bahrain and Kuwait compared to UAE, Saudi Arabia and Qatar — but growing. Opportunities exist primarily at university-affiliated hospitals and select MOH facilities.

• Oman: Sultan Qaboos University Hospital runs the most active research programme. Oman MOH Research Ethics Committee oversees all trials. Licensing via Oman Medical Speciality Board for nurses.
• Bahrain: Arabian Gulf University and Bahrain Defence Force Hospital have research units. Bahrain requires MOH nursing registration.
• Kuwait: Kuwait University Health Sciences Centre and select MOHP hospitals run trials. Registry on the Kuwait Medical Commission required.
• All three countries apply ICH-GCP principles for internationally sponsored trials

The study protocol is the master document governing every aspect of a trial. CRCs must read, understand and implement every detail of the protocol — eligibility criteria, visit schedules, assessment windows, prohibited medications, and stopping rules. Protocol deviations (unplanned departures from the protocol) must be identified, reported to the IRB/REC and sponsor, and documented with corrective actions.

• Maintain protocol version control — ensure all staff are working from the current approved version
• Create site-specific visit checklists and procedure manuals derived from the protocol
• Understand the distinction between protocol deviations (minor, unintentional) and protocol violations (more serious, may affect subject safety or data integrity)
• Know the assessment windows for each visit and proactively schedule participants to avoid out-of-window visits
• Attend investigator meetings (IMs) and teleconferences to stay updated on protocol amendments

Patient recruitment is often the most challenging aspect of clinical trial management. CRCs must systematically identify potentially eligible participants, review inclusion and exclusion criteria rigorously, and ensure all screening procedures are conducted within protocol-specified windows.

• Develop recruitment strategies: liaising with referring physicians, reviewing clinic lists, poster campaigns (IRB-approved)
• Screen logs: maintain accurate records of all screened participants including reasons for screen failure — this data is reported to sponsors
• Screen failure rates vary widely by indication; oncology trials often have high screen failure rates due to complex molecular eligibility criteria
• Understand the ethical principle: recruitment must never feel coercive — participants have the right to decline without impact on their clinical care
• Track enrollment against site targets; communicate anticipated shortfalls to sponsors proactively

Informed consent in the GCC requires careful cultural and linguistic adaptation beyond standard Western practice. The informed consent form (ICF) must be in the participant's primary language, comprehension must be confirmed, and the process must be entirely voluntary with adequate time for questions.

• Arabic consent forms: All ICFs must be translated into Arabic with verified back-translation; translation must be IRB/REC-approved
• Literacy: Some GCC participant populations have limited literacy — oral consent with an impartial witness is required in these situations, documented appropriately
• Family involvement: In GCC culture, patients often want family members present and involved in medical decisions. While the individual participant must consent autonomously, accommodating family presence is respectful and appropriate
• Re-consent is required whenever the ICF is amended — track consent versions meticulously
• Document who obtained consent, when, where, and that the participant had adequate time for questions
• Participants may withdraw consent at any time without affecting their clinical care — document withdrawals and their reason

CRCs with clinical backgrounds are uniquely positioned to perform study procedures, reducing the burden on investigator physicians. Competency must be formally documented for each procedure and held on file for inspection.

• Blood draws: Venepuncture for PK (pharmacokinetic) sampling, routine safety bloods, and special assay samples. Critical attention to sample labelling, time of draw documentation, and centrifuge/storage requirements
• ECG: 12-lead ECG acquisition for cardiac safety monitoring, particularly in oncology trials with QTc-prolonging agents
• Investigational Product (IP) administration: Where permitted by scope of practice and protocol — oral IP dispensing, IV administration in Phase I units, injection administration with double-check procedures
• Vital signs: Blood pressure, HR, temperature, SpO2, respiratory rate — often required at specific protocol-mandated time points
• Questionnaires: Patient-Reported Outcomes (PROs), Quality of Life scales — administer in standardised manner per protocol

Data quality is the product of meticulous documentation. The principle of ALCOA+ governs all research data: Attributable, Legible, Contemporaneous, Original, Accurate — plus Complete, Consistent, Enduring, and Available.

• Source documents: Original medical records, nursing notes, lab reports — the primary record from which CRF data is transcribed. Must be retained per protocol-specified timelines (often 15+ years)
• CRF/eCRF completion: Electronic data capture (EDC) systems — Medidata Rave, Oracle InForm, REDCap — require timely, accurate data entry; most sites target <2 days from assessment to data entry
• Query management: Sponsor monitors raise data queries when CRF data is missing, inconsistent or unclear. CRCs must respond to queries promptly with appropriate source document justification
• Never alter source documents — use transparent corrections with single line, initials, date and reason
• IP (Investigational Product) accountability: meticulous dispensing records, reconciliation logs, and return/destruction documentation

Adverse event (AE) and Serious Adverse Event (SAE) reporting is one of the most critical CRC responsibilities. Failures in SAE reporting are among the most serious GCP deviations and can lead to trial suspension and regulatory action.

• Adverse Event (AE): Any untoward medical occurrence in a trial participant — does not necessarily have a causal relationship with the study treatment
• Serious Adverse Event (SAE): Any AE that results in death, is life-threatening, requires hospitalisation, results in persistent disability, or is a congenital anomaly. SAEs have strict reporting timelines — typically within 24 hours of the site becoming aware
• SAEs must be reported to: sponsor (via defined route), IRB/REC (per local requirements), and regulatory authority where applicable
• CRCs must understand causality assessment and expectedness: is the SAE related to the investigational product? Is it listed in the Investigator's Brochure?
• Maintain a complete AE log for each participant; ensure all AEs are followed to resolution or stable state
• CTCAE grading (Common Terminology Criteria for Adverse Events) — standard grading system for oncology trials: Grade 1 (mild) to Grade 5 (death)

The Investigator Site File (ISF) — also called the Site Master File or Trial Master File (TMF) at the sponsor level — is the complete documentary record of the trial at your site. It must be maintained in a state of continuous inspection readiness.

• ISF essential documents: protocol and amendments, ICF versions, IRB/REC approvals, CV and GCP certificates of all research staff, IP accountability records, monitoring visit reports, correspondence with sponsor and IRB
• Regulatory inspections (FDA, EMA, national health authorities) can occur at any time during or after a trial. Sites involved in US-registered trials are subject to FDA Bioresearch Monitoring Program (BIMO) inspections
• IRB/REC audits: local ethics committees may conduct site audits, especially for high-risk trials or where concerns have been raised
• Maintain delegation logs: document which staff members are authorised to perform which study activities — this log is critical during inspection
• Keep CVs and GCP certificates of all study staff current — expired documents in the ISF are a common inspection finding

CRAs from the sponsor or CRO conduct regular monitoring visits to verify that the trial is being conducted per protocol and GCP. These visits are your opportunity to demonstrate site excellence and resolve data queries.

• Site Initiation Visit (SIV): Before first participant enrolled — sponsor reviews site readiness, trains staff on protocol and EDC, and confirms regulatory documents are in order
• Routine monitoring visits: Scheduled periodically based on risk assessment. CRA reviews source documents, verifies CRF data, checks IP accountability, and reviews the ISF
• Close-Out Visit (COV): At study completion — final IP reconciliation, ISF review, and archiving instructions
• Investigator Meetings: Sponsor-organised meetings bringing together all sites — excellent networking opportunity and source of protocol updates
• Prepare for monitoring visits by having all source documents accessible and CRF data up to date

The GCC has among the world's highest rates of type 2 diabetes mellitus (T2DM), with UAE and Saudi Arabia frequently cited at 20–30% adult prevalence. This massive patient population makes the region extremely attractive for diabetes drug development trials — particularly novel GLP-1 agonists, SGLT-2 inhibitors, dual/triple receptor agonists, and diabetes complication prevention studies.

• Dubai Diabetes Centre, Imperial College London Diabetes Centre (Abu Dhabi), and multiple HMC endocrinology units run active diabetes trials
• Research nurses in diabetes trials require competency in HbA1c monitoring, continuous glucose monitoring (CGM) device application, mixed meal tolerance tests, and insulin titration protocols
• Novo Nordisk, Eli Lilly, Sanofi, and AstraZeneca all have active diabetes trial programmes in the GCC
• Diabetic kidney disease, retinopathy, and neuropathy are common complication-related trial areas
• Ramadan fasting studies are a unique GCC-specific research area — investigating glucose management during religious fasting

Cancer incidence is rising across the GCC as populations age and lifestyle patterns change. KFSH Riyadh runs the most comprehensive oncology trial programme in the region, covering solid tumours, haematological malignancies, and BMT-related research. Cleveland Clinic Abu Dhabi's cancer centre runs trials aligned with the US Cleveland Clinic network.

• Oncology CRC roles typically require prior oncology nursing experience and CTCAE competency for adverse event grading
• Phase I oncology trials require nursing competencies in first-in-human drug administration, dose-limiting toxicity assessment, and rapid response to infusion reactions
• Immunotherapy trials (checkpoint inhibitors: pembrolizumab, nivolumab, atezolizumab) are a major and growing area — immune-related adverse events (irAEs) require specialised nursing assessment
• Haematology/BMT research at KFSH includes CAR-T cell therapy trials — one of the most complex CRC roles in the field
• AstraZeneca's Oncology business has an active GCC trial presence; Roche and MSD also run significant oncology studies at GCC sites

Cardiovascular disease is the leading cause of death across the GCC, driven by high rates of diabetes, hypertension, obesity, and dyslipidaemia. This creates large patient populations for heart failure, atrial fibrillation, acute coronary syndrome, and lipid-lowering trials.

• HMC's Heart Hospital in Doha is an active cardiac trial site — research nurses here require ECG proficiency, haemodynamic monitoring competency, and familiarity with cardiac biomarker panels
• KFSH Cardiac Sciences Programme runs both investigator-initiated and industry-sponsored cardiovascular trials
• SGLT-2 inhibitor cardiovascular outcomes studies have been highly active — GCC sites contributed to landmark trials including DAPA-HF and EMPEROR-Reduced
• Echocardiography data collection, 6-minute walk test, and NYHA class assessment are common CRC competencies for heart failure trials

The GCC has significantly higher rates of consanguineous marriages than Western populations, resulting in elevated prevalence of autosomal recessive genetic disorders. This has positioned KFSH Riyadh as a global leader in rare genetic disease research, with a unique patient population for conditions rare elsewhere.

• Conditions of particular research interest include: sickle cell disease (high prevalence in Saudi Arabia and Oman), thalassaemia, familial hypercholesterolaemia (extremely high rates in certain Gulf populations), and various rare metabolic disorders
• Gene therapy and gene editing trials (e.g., for sickle cell disease) are among the most exciting current areas — KFSH has been involved in early-access programmes for novel gene therapies
• Lysosomal storage disorders, primary immune deficiencies, and rare bone marrow failure syndromes are active research areas at KFSH
• Research nurses in this area require comfort with complex genetic counselling frameworks, long-term follow-up protocols, and sensitive family-based consent processes

The COVID-19 pandemic accelerated GCC clinical trial infrastructure significantly. The UAE, Qatar and Saudi Arabia all ran national vaccine and treatment trials during the pandemic, training a new generation of research nurses and establishing institutional research capacity that continues to be used post-pandemic.

• The UAE participated in the Phase III trials for the Sinopharm/BBIBP-CorV COVID-19 vaccine — one of the largest GCC trial programmes ever conducted
• Post-pandemic research infrastructure is now being applied to Long COVID studies, respiratory virus research, and novel antimicrobial trials
• MERS-CoV (Middle East Respiratory Syndrome) remains an area of unique GCC research relevance — particularly relevant in Saudi Arabia near camel exposure areas
• Antimicrobial resistance (AMR) is a growing GCC research priority given high antibiotic usage rates

Sidra Medicine Qatar is the region's premier centre for women's and children's health research. As a WHO Collaborating Centre and Weill Cornell Medicine affiliate, Sidra runs high-quality research in maternal health, reproductive medicine, obstetric complications, and neonatal outcomes.

• Active research areas include: gestational diabetes management, pre-eclampsia prevention, preterm labour interventions, and neonatal neurodevelopmental outcomes
• Polycystic ovary syndrome (PCOS) — extremely common in the GCC — is an active area for trials of novel hormonal interventions
• Research nurses at Sidra require expertise in obstetric monitoring, neonatal assessment, and culturally sensitive approaches to women's health research
• The Qatar Genome Programme (QGP) has generated population-level genomic data creating unique opportunities for GCC-specific women's health research